Svelta Labs
Peptide library Metabolic & Weight

Tirzepatide

Also known as: Dual GIP/GLP-1 agonist

A dual incretin agonist studied extensively for weight management, glucose control and appetite regulation.

  • GIP
  • GLP-1
  • Appetite regulation
What it is

Plain-English overview

Tirzepatide activates both GIP and GLP-1 receptors. It is one of the most important modern metabolic research compounds.

Mechanism

How it is thought to work

The paired incretin signal influences satiety, gastric emptying and glucose handling. Research suggests the combined pathway can outperform GLP-1-only signalling for some endpoints.

Studied for

Research interest areas

  • Weight-management outcomes
  • Blood-sugar control
  • Food-intake reduction
Evidence

What the research suggests

Large human trials give tirzepatide a strong evidence base for metabolic outcomes. Gastrointestinal side effects are common in trial reporting.

A note on safety. This content is educational and is not medical advice. Many peptides and adjacent compounds are research materials and may not be approved medicines. Speak with a qualified healthcare professional before considering anything discussed here.